Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain

← catalyst calendar

NCT06810245

Sponsored by Contineum Therapeutics (industry) · CTNM — their whole pipeline →.

Phase

Phase 1

Status

Completed

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

43actual

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-02-04

actual

When the study began enrolling

Primary completion

2026-01-20

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-01-20

actual

The whole study's end, after follow-up

First posted

2025-02-05

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-03-18

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Chronic Osteoarthritis Pain
Chronic Low Back Pain

Interventions

Drug: PIPE-791
Drug: Placebo

Primary outcome

what the primary-completion date above is the date OF

Number of subjects with Treatment-emergent adverse events (TEAEs)

measured For Treatment Period 1, from Baseline (Day 1) to End of Treatment Period 1 (TP1; Day 29), for Treatment Period 2, from Baseline of Treatment Period 2 (TP2; Day 29) to End of TP2 (Day 57).

Publications

PMID 42370792 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · CTNM's whole pipeline · Catalyst calendar · Every registered study · What changed